Clinical and preclinical investigation of CJC-1295 without DAC—chemically designated as Modified GRF 1-29—focuses on its capacity to elicit natural, pulsatile growth hormone secretion by targeting pituitary GHRH receptors. Researchers evaluating secretagogue dynamics analyze its pharmacokinetic profile, half-life extensions over native GHRH, and downstream IGF-1 expression in laboratory settings. Understanding the scientific literature surrounding cjc-1295 no dac human trial data provides essential context for designing controlled in vitro and animal research models.
Clinical and preclinical investigation of CJC-1295 without DAC—chemically designated as Modified GRF 1-29—focuses on its capacity to elicit natural, pulsatile growth hormone secretion by targeting pituitary GHRH receptors. Researchers evaluating secretagogue dynamics analyze its pharmacokinetic profile, half-life extensions over native GHRH, and downstream IGF-1 expression in laboratory settings. Understanding the scientific literature surrounding cjc-1295 no dac human trial data provides essential context for designing controlled in vitro and animal research models.
Human clinical trials evaluating tetrasubstituted growth hormone-releasing hormone (GHRH 1-29) derivatives—commonly designated as CJC-1295 No DAC or Modified GRF 1-29—demonstrated that the compound stimulates acute, pulsatile growth hormone (GH) elevation and increases circulating IGF-1 concentrations without disrupting basal hormone secretion patterns. Unlike DAC-bound variants that prolong plasma clearance to days, CJC-1295 No DAC exhibits a brief biological half-life (~30 minutes), mimicking endogenous GHRH kinetics.
When evaluating the broader body of clinical literature, it is critical to distinguish between trials examining the original ConjuChem formulation (which incorporated the Drug Affinity Complex bioconjugate to bind serum albumin) and foundational human endocrinology studies assessing tetrasubstituted GHRH (1-29) peptides. Studies investigating the tetrasubstituted non-DAC peptide confirmed that strategic amino acid replacements prevent rapid degradation by dipeptidyl peptidase IV (DPP-IV), thereby extending the terminal half-life from less than 12 minutes (native GHRH) to roughly 30 minutes in human subjects. This altered pharmacokinetic window allows somatotroph receptors in the anterior pituitary to undergo physiological stimulation while preserving the normal feedback loop governed by endogenous somatostatin.
CJC-1295 without DAC is a synthetic 29-amino acid peptide representing the truncated, biologically active N-terminal core of human Growth Hormone Releasing Hormone (GHRH 1-44). In its unmodified state, natural GHRH 1-29 (sermorelin) is rapidly cleaved in plasma between the second (Ala) and third (Asp) residues by the ubiquitous metabolic enzyme dipeptidyl peptidase IV. To overcome this systemic metabolic fragility in research models, pharmaceutical chemists engineered a tetrasubstituted variant.
The molecular architecture of CJC-1295 No DAC includes four specific amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. The substitution of D-Ala at position 2 sterically hinders DPP-IV enzymatic cleavage, while the remaining substitutions optimize helical secondary structure, binding affinity, and resistance to chemical oxidation. In biochemical assays, these structural modifications maintain receptor selectivity for the GHRH receptor while significantly enhancing plasma stability relative to native peptide fragments. Researchers interested in broader peptide classification can consult our GHRH analogs overview for structural comparative data.
At the cellular level, CJC-1295 No DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a seven-transmembrane G-protein coupled receptor expressed predominantly on pituitary somatotrophs. Upon receptor binding, the peptide stimulates the Gs alpha subunit, which activates membrane-bound adenylate cyclase. This cascade leads to intracellular accumulation of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA).
The downstream signaling pathway triggers the opening of L-type voltage-gated calcium channels, promoting an influx of extracellular calcium that drives the exocytosis of pre-stored growth hormone granules. Preclinical models indicate that because CJC-1295 No DAC lacks a permanent covalent albumin binder, its cellular dissociation rate allows somatotrophs to reset between pulses. This maintains the physiological rhythm of GH release and prevents continuous receptor internalisation or down-regulation—a phenomenon frequently analyzed in endocrinology research models.
When designing comparative secretagogue protocols, researchers frequently contrast CJC-1295 No DAC with long-acting constructs such as CJC-1295 with DAC, as well as short-acting analogs like Sermorelin and specialized analogs like Tesamorelin. The presence or absence of the Drug Affinity Complex (DAC)—a maleimidopropionic acid reactive group attached to the Lys30 residue—fundamentally alters peptide half-life, receptor dynamics, and systemic clearance rates in trial literature.
Unmodified Sermorelin possesses a biological half-life of approximately 8 to 12 minutes due to swift DPP-IV cleavage. CJC-1295 No DAC achieves a half-life of 30 minutes through tetrasubstitution, providing an optimized window for acute stimulation without inducing continuous baseline elevation. Conversely, CJC-1295 with DAC forms a covalent bond with circulating serum albumin, extending its biological half-life to 6–8 days in human subjects. While long-acting DAC constructs generate sustained GH and IGF-1 plateau levels, non-DAC formulations are specifically chosen in research settings where mimicking natural episodic GH secretion patterns is paramount.
In animal models and in vitro tissue studies, the acute growth hormone pulses elicited by CJC-1295 No DAC act on hepatic GH receptors to stimulate transcription and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 serves as the primary mediator of GH-dependent anabolic and regenerative signaling in peripheral tissues.
Preclinical data indicate that elevated circulating IGF-1 activates the PI3K/Akt and MAPK/ERK signaling pathways in target cells. In musculoskeletal research models, this activation is associated with increased nitrogen retention, accelerated myoblast proliferation, and enhanced collagen synthesis in connective tissues. Furthermore, rodent models evaluating metabolic activity demonstrate shifts in substrate oxidation, favoring lipolysis in adipose tissue and protein conservation in skeletal muscle mass during short-term administration protocols.
In secretagogue research, CJC-1295 No DAC is frequently evaluated in conjunction with Growth Hormone Releasing Peptides (GHRPs) or ghrelin receptor agonists, such as Ipamorelin. These two classes of compounds target complementary, non-competing receptor pathways on the pituitary somatotroph and hypothalamus.
While CJC-1295 No DAC operates via the GHRH receptor/cAMP/PKA pathway, ghrelin mimetics act through the Growth Hormone Secretagogue Receptor (GHS-R1a), which couples to the Gq subunit and utilizes the phospholipase C (PLC) / inositol trisphosphate (IP3) signaling cascade. Preclinical studies demonstrate that simultaneous activation of GHRH-R and GHS-R1a yields a synergistic—rather than merely additive—release of growth hormone. Co-administration models also indicate that ghrelin mimetics can temporarily blunt endogenous somatostatin inhibition, allowing CJC-1295 No DAC to exert maximum receptor stimulation during the experimental window.
To ensure reproducible quantitative data in laboratory experiments, research compounds must strictly comply with comprehensive analytical verification standards. In consistent scientific testing, subtle impurities, truncated peptide sequences, or residual organic solvents can compromise receptor binding studies and confound cellular assays.
PX1 Research mandates rigorous quality assurance for every single lot manufactured in our USA-based facilities. Each batch of CJC-1295 No DAC undergoes independent third-party analysis using reverse-phase high-performance liquid chromatography (RP-HPLC) to verify chemical purity at or exceeding 98.0%. Electrospray ionization mass spectrometry (ESI-MS) is utilized to confirm exact molecular weight and sequence integrity, while Chromogenic Reagent LAL Endotoxin Testing guarantees endotoxin limits remain strictly below regulatory thresholds (<0.05 EU/mg). Principle investigators can review analytical protocols in our guide to HPLC and mass spectrometry testing or browse our complete catalog of all research peptides.
Proper handling and reconstituted stability are critical for maintaining peptide structural integrity in laboratory environments. CJC-1295 No DAC is supplied as a lyophilized (freeze-dried) sterile powder in sealed glass vials, stabilized under an inert gas atmosphere to prevent oxidative degradation during storage.
For laboratory assay preparation, lyophilized vials should be reconstituted using sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile research-grade diluent. The diluent should be introduced gently down the inner glass wall of the vial to minimize shear stress and foam formation, followed by gentle swirling rather than vigorous vortexing. Detailed reconstitution calculations and liquid handling parameters are outlined in our peptide reconstitution guide. For long-term preservation, unfulfilled lyophilized vials must be stored at -20°C or -80°C, while reconstituted solutions should be kept refrigerated at 2°C to 8°C and evaluated within short experimental windows. High-volume research laboratories managing bulk inventory requirements can explore options through our wholesale lab account portal.
What is the primary objective of cjc-1295 no dac human trial literature?
Clinical literature examining CJC-1295 without DAC focused on evaluating the pharmacokinetic enhancement achieved by tetrasubstitution over native GHRH (1-29), measuring acute growth hormone release peaks, clearance rates, and downstream serum IGF-1 responses in clinical settings.
How does CJC-1295 No DAC differ structurally from CJC-1295 with DAC?
CJC-1295 No DAC contains four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that protect against enzymatic degradation by DPP-IV. CJC-1295 with DAC contains these same four substitutions plus a Lys30 residue bound to a Drug Affinity Complex (DAC) reactive group, which forms a covalent bond with blood albumin to extend half-life to several days.
What is the biological half-life of CJC-1295 No DAC in research literature?
In published human and animal pharmacokinetic studies, CJC-1295 No DAC exhibits a biological half-life of approximately 30 minutes, compared to 8–12 minutes for native GHRH/Sermorelin and 6–8 days for CJC-1295 with DAC.
Why is CJC-1295 No DAC frequently paired with Ipamorelin in preclinical models?
CJC-1295 No DAC acts on GHRH receptors, while Ipamorelin acts on ghrelin (GHS-R1a) receptors. Preclinical research shows that activating both intracellular pathways simultaneously produces a synergistic release of growth hormone greater than the sum of either compound administered individually.
What purity parameters are confirmed in PX1 Research Certificate of Analysis (COA)?
Every lot of CJC-1295 No DAC provided by PX1 Research includes a lot-specific COA verifying ≥98% purity by RP-HPLC, correct molecular mass via mass spectrometry (ESI-MS), and bacterial endotoxin levels below 0.05 EU/mg.
How should CJC-1295 No DAC be stored upon receipt in the laboratory?
Lyophilized CJC-1295 No DAC should be stored in a freezer at -20°C or -80°C protected from light. After reconstitution with bacteriostatic water, the liquid solution should be refrigerated at 2°C to 8°C and used within specified experimental timeframes.
Does CJC-1295 No DAC suppress natural physiological somatostatin feedback loops?
Because CJC-1295 No DAC has a short biological half-life (~30 minutes), it clears rapidly enough to allow endogenous somatostatin (SRIF) to exert its natural inhibitory feedback, preserving physiological episodic GH pulses unlike ultra-long-acting analogs.
Is CJC-1295 No DAC identical to Modified GRF 1-29?
Yes, in biochemical and peptide literature, 'Modified GRF 1-29' and 'CJC-1295 No DAC' refer to the exact same tetrasubstituted 29-amino acid GHRH analog.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.